Ignite Creation Date:
2024-05-06 @ 3:28 PM
Last Modification Date:
2024-10-26 @ 1:50 PM
Study NCT ID:
NCT04641754
Status:
UNKNOWN
Last Update Posted:
2020-11-24
First Post:
2020-11-11
Brief Title:
A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive or ROS1-positive Non-small Cell Lung Cancer
Sponsor:
Qilu Pharmaceutical Co Ltd
Organization:
Qilu Pharmaceutical Co Ltd
Study Overview
Official Title:
Phase II Clinical Study to Evaluate the Efficacy and Safety of WX-0593 in Patients With Crizotinib-resistant ALK -Positive or Crizotinib-resistantCrizotinib-naive ROS1-positive Non-small Cell Lung Cancer NSCLC
Status:
UNKNOWN
Status Verified Date:
2020-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate safety and efficacy of WX-0593 oral tablets in ALK -positive or ROS1-positive non-small cell lung cancer NSCLC
Detailed Description:
The clinical study is a single-arm phase II open label multicenter design in patients with crizotinib-resistant ALK -positive or crizotinib-resistantcrizotinib-naive ROS1-positive NSCLC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None